Biosig Technologies (NASDAQ:STEX) Major Shareholder Frank Giustra Buys 100,000 Shares

Biosig Technologies, Inc. (NASDAQ:STEX) major shareholder Frank Giustra acquired 100,000 shares of the company’s stock in a transaction dated Wednesday, February 4th. The stock was acquired at an average cost of $3.17 per share, for a total transaction of $317,000.00. Following the completion of the purchase, the insider directly owned 1,278,205 shares in the company, valued at $4,051,909.85. This trade represents a 8.49% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Frank Giustra also recently made the following trade(s):

• On Friday, January 23rd, Frank Giustra bought 1,000,000 shares of Biosig Technologies stock. The stock was acquired at an average price of $3.00 per share, with a total value of $3,000,000.00.

Biosig Technologies Stock Performance

STEX traded down $0.19 during trading on Wednesday, hitting $3.13. The company’s stock had a trading volume of 5,436,828 shares, compared to its average volume of 1,914,612. The firm has a market cap of $499.56 million, a PE ratio of -2.32 and a beta of 1.50. Biosig Technologies, Inc. has a twelve month low of $0.40 and a twelve month high of $14.11.

Wall Street Analyst Weigh In

Separately, Weiss Ratings initiated coverage on shares of Biosig Technologies in a report on Friday, January 23rd. They set a “sell (d-)” rating on the stock. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Biosig Technologies presently has an average rating of “Sell”.

About Biosig Technologies

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.